{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 48,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/28",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.53,
        "w": 0.38,
        "x": 0.52,
        "y": 0.36
      },
      "kind": "image",
      "text": "IgG 149 kDa scFv (OCS-02) Regions that bind to neutralize TNFα 26 kDa",
      "attrs": {},
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e6368f7-5e73-4574-86d0-667d2cae671c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.039,
        "w": 0.109,
        "x": 0.85,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c7119f5-42a5-47b4-ad4f-06cf53a56d68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.42,
        "x": 0.047,
        "y": 0.79
      },
      "kind": "list",
      "text": "Proprietary genetic biomarker Associated with OCS-02 response highlighting opportunity for a precision treatment in DED",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "163d223e-2601-4994-97ed-580380d8c095",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.42,
        "x": 0.047,
        "y": 0.44
      },
      "kind": "list",
      "text": "Clinically proven MoA Anti-inflammation and anti-necrosis MoA approved as systemic treatment for ocular disease and with transformative impact in other areas",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c743f22-ed04-4498-b9e7-bb172d18ac09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.42,
        "x": 0.047,
        "y": 0.313
      },
      "kind": "list",
      "text": "OCS-02 is an anti-TNFa antibody fragment formulation with potential to become the first approved topical biologic for DED",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfec883a-440e-49e5-b795-0a20989b9187",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.42,
        "x": 0.047,
        "y": 0.62
      },
      "kind": "list",
      "text": "Enhanced ocular penetration Lower molecular weight, enhanced ocular penetration and higher concentration",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f999accc-07a3-4bed-8c79-75571d56154a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.02,
        "x": 0.936,
        "y": 0.94
      },
      "kind": "metric",
      "text": "28",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41c0ffd2-d5e5-4e7f-83eb-73fa5e51c432",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.29,
        "x": 0.12,
        "y": 0.235
      },
      "kind": "other",
      "text": "Topical Biologic Candidate",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7485b193-5077-4a7d-87bd-3300c06660f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.54,
        "y": 0.235
      },
      "kind": "other",
      "text": "Innovative Antibody Fragment Technology",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf9a2afd-0032-4446-a2e6-b87286089000",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.149,
        "x": 0.776,
        "y": 0.743
      },
      "kind": "paragraph",
      "text": "Framework for OCS-02 optimized for stability and other drug-like properties",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45b5c68b-8a81-4a2b-a879-ef494c2bf08a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.824,
        "x": 0.026,
        "y": 0.08
      },
      "kind": "title",
      "text": "Clinically proven MoA with potential transformative impact in ocular inflammatory diseases",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07f15230-e60e-433b-9429-c13eef2d0f9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.039,
        "w": 0.79,
        "x": 0.026,
        "y": 0.04
      },
      "kind": "title",
      "text": "OCS-02 | Novel anti-TNFα Eye Drop for Ocular Inflammation",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b7b360c-9f93-41f1-aed7-795634c97bd8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 28,
      "beatId": "a2576958-ca6f-43c8-8aa4-05628f10fd15",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents OCS-02, a novel anti-TNFα eye drop",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}